Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  therapeutic autologous lymphocytes
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 80 and under
Trial IDs: MULTIPRAT, NCI-2012-00636, 23637-MULTIPRAT, H-23637, NCT00840853
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
MAGE A10?7?6T for Advanced NSCLC
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ADP 0022-003, NCI-2016-00533, NCT02592577
Genetically Engineered Autologous T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 03712, NCI-2012-03024, NCT01747486
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients with Metastatic Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-1055, NCI-2014-01040, NCT02027935
CART-19 Cells in Treating Patients With Chemotherapy Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC13413, NCI-2014-00173, 818607, NCT02030834
Laboratory-Treated T-Cells in Treating Patients With Chemotherapy-Resistant or Refractory B-Cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 21413, NCI-2014-00172, UPCC 21413, NCT02030847
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CCTL019C2201, NCI-2015-01461, 2014-003060-20, NCT02445248
Depleted Immune Suppressor Stem Cell Transplant in Enhancing Immune Response To Vaccines in Patients with Multiple Myeloma
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: WINSHIP2905-15, NCI-2015-00743, IRB00079982, NCT02700841
Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: CHARKALL, NCI-2012-00845, H-23574, H-23574-CHARKALL, NCT00881920
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RENAL0027, NCI-2013-01688, NCT01943188
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CM-14-001, NCI-2015-00502, 5R44HL099217-03, NCI-2015-00503, NCT02203825
Expanded Natural Killer Cell Infusion in Treating Younger Patients with Recurrent/Refractory Brain Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 21 and under
Trial IDs: 2013-0765, NCI-2014-02677, NCT02271711
Start Over